| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
Phase 3 data readout example | Phase 3 | — | Subscribe to access the data. | Biologics | Rare Diseases | ||
Phase 3 data readout example | Phase 3 | — | Subscribe to access the data. | Biologics | Rare Diseases | ||
Phase 3 data readout example | Phase 3 | — | Subscribe to access the data. | Biologics | Rare Diseases |
Recent Updates
Recently added Catalysts
Astria Therapeutics, Inc.$12.58
+0.1 (+0.8%)
D 35Pipeline Score Overvalued Pharma · Clinical
Market Cap
718.13 M
EPS
-2.15
P/E Ratio
-
Value Trade
40.15 M
SEC Financials
Q3 2025Dilution Risk
40%Revenue
706.00 K
R&D Expenses
24.15 M
Total Assets
271.87 M
Total Liabilities
38.61 M
Equity
233.25 M
-1.8 %
Week
-2.56 %
1 Month
-0.08 %
3 Month
89.74 %
6 Month
-23.76 %
5 Year
-98.35 %
All Time
Cash Data
Cash Position
227.72 M
Monthly Burn
11.37 M
Runway
11.4 mo
Burn Trend
StableSEC Filing
Nov 12, 2025
Overview
Volume
3.20 M
52 Week Range
3.56 - 13.29
% held by Insiders
12.34 %
% held by Institutions
79.39 %
Enterprise Value
590.19 M
Total Shares
56.41 M
Short %
9.16 %
Float Shares
45.70 M
Company Description
locked
Upcoming Catalyst
Past FDA Catalysts & PDUFA Decisions
| Date | Drug | Catalyst | Stage | Outcome | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|---|
2025-03-02 | navenibart (STAR-0215) | phase 1b/2 data readout | Phase 1b/2 | — | – | – | – |
2025-03-02 | navenibart (STAR-0215) | phase 1b/2 data readout | Phase 1b/2 | — | – | – | – |
2025-03-02 | navenibart (STAR-0215) | phase 1b/2 data readout | Phase 1b/2 | — | – | – | – |
Drug Pipeline Intelligence
D35
Pipeline Score $196M
Pipeline ValueOvervalued
Valuation Signal3
Drugs Scored0.3x
rNPV / MCap Top 50%
Micro Cap (rank 462 of 923)
Percentile RankAstria Therapeutics, Inc. faces pipeline headwinds (35/100), with $702M risk-adjusted pipeline value, led by navenibart in Hereditary Angioedema (HAE) (Phase 3).
Showing 1 of 1 assets
| Drug | Indication | Phase | NCT ID | PTRS | rNPV | Status | Enrollment | Velocity | Design | Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| navenibart Small molecule | Hereditary Angioedema (HAE) | Phase 3 | NCT06842823 | 58% | $363M | ACTIVE NOT_RECRUITING | 302 | VERY_FAST | B (66) | Jun 1, 2027 | - | MEDIUM Jun 30, 2026 |
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
STAR-0215 | hereditary angioedema | Phase 1a | 2022-12-15 | well-tolerated at all doses studied; estimated half-life of STAR-0215 up to 110 days; sustained target engagement with plasma kallikrein inhibition for at least three months Read More | Astria Therapeutics Announces Positive Preliminary Results from the Phase 1a Clinical Trial of STAR-0215 in Healthy Subjects -- Shown Early Proof of Concept of STAR-0215's Profile as a Long-Acting Plasma Kallikrein Inhib Read More | |
STAR-0215 | hereditary angioedema | Phase 1a | 2022-12-15 | well-tolerated at all doses studied; estimated half-life of STAR-0215 up to 110 days; sustained target engagement with plasma kallikrein inhibition for at least three months Read More | Astria Therapeutics Announces Positive Preliminary Results from the Phase 1a Clinical Trial of STAR-0215 in Healthy Subjects -- Shown Early Proof of Concept of STAR-0215's Profile as a Long-Acting Plasma Kallikrein Inhib Read More | |
STAR-0215 | hereditary angioedema | Phase 1a | 2022-12-15 | well-tolerated at all doses studied; estimated half-life of STAR-0215 up to 110 days; sustained target engagement with plasma kallikrein inhibition for at least three months Read More | Astria Therapeutics Announces Positive Preliminary Results from the Phase 1a Clinical Trial of STAR-0215 in Healthy Subjects -- Shown Early Proof of Concept of STAR-0215's Profile as a Long-Acting Plasma Kallikrein Inhib Read More |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in ATXS
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
ATXS Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
Competitive Position
How ATXS ranks across every disease it competes inCompetitive Position is a premium feature
See how ATXS ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial